Journal: bioRxiv
Article Title: Chryseobacterium indologenes mediates resistance to osimertinib by activating the IGF1R pathway in EGFR-mutant lung adenocarcinoma
doi: 10.1101/2025.10.08.681060
Figure Lengend Snippet: (A) Phosphorylation of a panel of 49 RTKs was tested in a RTK array. PC9, HCC827, H1650 and H1975 cells, were treated with osimertinib (50 nM, 25 nM, 5 uM and 5 uM, respectively and C. indologenes PCM (100x dilution) for 24h. (B) Western blot of indicated proteins in PC9 cells treated with osimertinib (50 nM) and PCM (100x dilution) for 24h. (C) CCK-8 cell viability assay following treatment with indicated concentrations of IGF1 and IGF2 in PC9 cells. The assay was performed after 3 days of co-incubation. (D) Western blot of indicated proteins in PC9 cells after cells were treated with osimertinib (50 nM) and IGF1 and IGF2 (100 ng/ml) for 24h. (E) Cell viability assay of PC9 cells with knockdown of IGF1R (siIGF1R), MET (siMET) or both IGF1R and MET (siIGF1R +siMET). Cells were treated with osimertinib with or without C. indologenes PCM. (F) Western blot of indicated proteins in PC9 cells treated with siIGF1R, siMET for 24h. (G) CCK-8 cell viability assay following treatment with indicated concentration of osimertinib (10 nM) and linsitinib in PC9 cells, (H) Drug sensitivity assay was performed after 3 days treatment with osimertinib in siIGF1R-PC9 and siMET-PC9 cells.
Article Snippet: To assess whether IGF1R activation mediates resistance in LACs, cells were treated with recombinant human IGF1 (R&D Systems) or IGF2 (R&D Systems) at 0-100 ng/mL for 3 days in the presence or absence of osimertinib.
Techniques: Phospho-proteomics, Western Blot, CCK-8 Assay, Viability Assay, Incubation, Knockdown, Concentration Assay, Sensitive Assay
Proteintech is a verified supplier 
